Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk Blog Post
[event_date_range]
Essentials of Model-informed Drug Development in Oncology Blog Post
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs. Read the blog to learn more…
A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition Blog Post
Abstract The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter serotonin from neuronal synapses and is an important pharmacological target for treating a variety...
Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patient Blog Post
In partnership with Ichnos, Certara developed a QSP model to determine the most suitable therapeutic dose for their tri-specific T-cell engager. Despite the absence of monkey PK and toxicology data,...
Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies Blog Post
Download PDF Learn more about Non-Animal Navigator™ Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies. View Non-Animal Navigator™Contact us You May Also Like...
Combining mechanistic modeling with machine learning to predict clinical scores in inflammatory bowel disease (IBD) Blog Post
[event_date_range] Certara to Participate in Upcoming Investor Conferences Blog Post
RADNOR, PA — April 29, 2025 -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:...
Outsourcing in Clinical Trials East Coast 2025 Blog Post
[event_date_range] – [acf field="event_location"] – Booth [acf field="event_booth"]
